Automation solution for stem cell therapy

Automated personalized medicine production at fraunhofer IPT

Personalized (autologous) stem cell therapy is a promising approach in treatment of different diseases, though many technical issues must be solved.

To date, manufacturing therapeutic cells is time-consuming, labor-intensive, and susceptible to contamination and human error. Manufacturing cell products requires the development of efficient, cost-effective, and reproducible platforms. Automated, robotic, and closed production systems can address clinical-scale production of therapeutic cells effectively.
Robot arm manufacturing cell therapies in an automated system next to a NucleoCounter® NC-3000™.

GMP facilities need simple operations & consistent results

To fulfill their quality criteria, Fraunhofer IPT developed the AUTOSTEM platform – a closed, automated system for the manufacture of clinical-grade therapeutic mesenchymal stem cells (MSCs) grown on microcarriers. This robotic platform integrated the NucleoCounter® NC-3000™ for monitoring cell count and viability.

The NucleoCounter® NC-3000™ provides a robust and precise means to effectively determine viability and total cell count of MSCs. Cell sampling, staining and counting chamber loading are combined into a single step with the Via1-Cassette™, which ensures consistency and robustness between different users and measuring instruments.

Cell processing GMP facilities benefit from the instrument’s simple operation and consistent results. Furthermore, the NucleoCounter® NC-3000™ can be set to Remote Control Mode, whereby third-party control software can take over the instrument’s integration in automated setups. This makes it the perfect instrument for implementing in automated cell manufacturing processes.

Fraunhofer IPT developed the AUTOSTEM platform within its EU project of the same name. Find out more.